NCT06900114View on ClinicalTrials.gov

Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China

Active, not recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 7, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

October 31, 2025

Conditions

MucormycosisHematologic MalignanciesCOVID-19

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors

lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06900114 - Disease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China | Biotech Hunter | Biotech Hunter